Is it time to combine osteoporosis therapies?
نویسندگان
چکیده
منابع مشابه
Is it time to combine osteoporosis therapies?
www.thelancet.com Published online May 15, 2013 http://dx.doi.org/10.1016/S0140-6736(13)60984-8 1 Some therapies licensed to treat osteoporosis work by inhibiting bone turnover (anticatabolic agents) and some by stimulating bone formation (anabolic agents). In The Lancet, Joy Tsai and colleagues report an exciting new approach in which an anticatabolic drug, denosumab, is combined with an anabo...
متن کاملWriting qualitative article: It is time to quality improvement
Précis: This debate article highlights some questions from critics of qualitative research. Planning for proper design, philosophical background, researcher as a research instrument in the study, trustworthiness and application of findings are main debates in this field. One of the issues that have been received little attention is report of qualitative inquiry. A qualified report can an...
متن کاملI-4: Is It Time Now to Cancel Fresh EmbryoTransfer
The implantation of embryo depends on the quality of the embryo and the receptivity of the endometrium. While the factors affecting embryo quality were optimized, the implantation rates did not reach the desirable levels. This directs the blaming for endometrial receptivity which already has been affected by supra-physiological levels of hormone, namely estradiol, in controlled ovarian hypersti...
متن کاملIs it better to combine predictions?
We have compared the accuracy of the individual protein secondary structure prediction methods: PHD, DSC, NNSSP and Predator against the accuracy obtained by combing the predictions of the methods. A range of ways of combing predictions were tested: voting, biased voting, linear discrimination, neural networks and decision trees. The combined methods that involve 'learning' (the non-voting meth...
متن کاملIs it time to combine untargeted antifungal strategies to reach the goal of ‘early’ effective treatment?
A recently published retrospective study by Posteraro et al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as a strategy for antifungal drug administration in patients at high risk of candidemia. The strategy consisted of the administration of antifungals (anidulafungin in most cases) to septic patients with a Candida score ≥ 3 and a positive BDG result (≥80 pg/ml). This untargeted strateg...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet
سال: 2013
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(13)60984-8